NasdaqGM - Delayed Quote USD

Personalis, Inc. (PSNL)

1.2650 +0.0150 (+1.20%)
At close: April 26 at 4:00 PM EDT
1.2300 -0.04 (-2.77%)
After hours: April 26 at 4:13 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
73,481.0000
73,481.0000
65,047.0000
85,494.0000
78,648.0000
Cost of Revenue
55,273.0000
55,273.0000
51,697.0000
53,837.0000
58,534.0000
Gross Profit
18,208.0000
18,208.0000
13,350.0000
31,657.0000
20,114.0000
Operating Expense
114,502.0000
114,502.0000
128,881.0000
97,010.0000
62,260.0000
Operating Income
-96,294.0000
-96,294.0000
-115,531.0000
-65,353.0000
-42,146.0000
Net Non Operating Interest Income Expense
5,791.0000
5,791.0000
2,195.0000
183.0000
947.0000
Other Income Expense
-17,710.0000
-17,710.0000
61.0000
-42.0000
-24.0000
Pretax Income
-108,213.0000
-108,213.0000
-113,275.0000
-65,212.0000
-41,223.0000
Tax Provision
83.0000
83.0000
40.0000
14.0000
57.0000
Net Income Common Stockholders
-108,296.0000
-108,296.0000
-113,315.0000
-65,226.0000
-41,280.0000
Diluted NI Available to Com Stockholders
-108,296.0000
-108,296.0000
-113,315.0000
-65,226.0000
-41,280.0000
Basic EPS
-2.38
-2.25
-2.48
-1.49
-1.20
Diluted EPS
-2.38
-2.25
-2.48
-1.49
-1.20
Basic Average Shares
47,342.0810
48,175.2010
45,704.8050
43,886.7300
34,374.9030
Diluted Average Shares
47,342.0810
48,175.2010
45,704.8050
43,886.7300
34,374.9030
Total Operating Income as Reported
-109,936.0000
-109,936.0000
-115,531.0000
-65,353.0000
-42,146.0000
Total Expenses
169,775.0000
169,775.0000
180,578.0000
150,847.0000
120,794.0000
Net Income from Continuing & Discontinued Operation
-108,296.0000
-108,296.0000
-113,315.0000
-65,226.0000
-41,280.0000
Normalized Income
-97,518.8200
-97,518.8200
-113,315.0000
-65,226.0000
-41,280.0000
Interest Income
5,901.0000
5,901.0000
2,396.0000
367.0000
949.0000
Interest Expense
110.0000
110.0000
201.0000
184.0000
2.0000
Net Interest Income
5,791.0000
5,791.0000
2,195.0000
183.0000
947.0000
EBIT
-108,103.0000
-108,103.0000
-113,074.0000
-65,028.0000
-41,221.0000
EBITDA
-96,807.0000
-96,807.0000
-104,642.0000
-59,014.0000
-35,463.0000
Reconciled Cost of Revenue
55,273.0000
55,273.0000
51,697.0000
53,837.0000
58,534.0000
Reconciled Depreciation
11,296.0000
11,296.0000
8,432.0000
6,014.0000
5,758.0000
Net Income from Continuing Operation Net Minority Interest
-108,296.0000
-108,296.0000
-113,315.0000
-65,226.0000
-41,280.0000
Total Unusual Items Excluding Goodwill
-13,642.0000
-13,642.0000
--
--
--
Total Unusual Items
-13,642.0000
-13,642.0000
--
--
--
Normalized EBITDA
-83,165.0000
-83,165.0000
-104,642.0000
-59,014.0000
-35,463.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
-2,864.8200
-2,864.8200
--
--
--
12/31/2020 - 6/20/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CDNA CareDx, Inc
7.56
0.00%
 
TWST Twist Bioscience Corporation
31.54
+1.48%
 
VCYT Veracyte, Inc.
19.31
-0.87%
 
BDSX Biodesix, Inc.
1.2350
-1.98%
 
GH Guardant Health, Inc.
17.35
+1.11%
 
BNR Burning Rock Biotech Limited
0.8500
0.00%
 
FLGT Fulgent Genetics, Inc.
20.10
+0.35%
 
VNRX VolitionRx Limited
0.9137
+2.65%
 
NEO NeoGenomics, Inc.
14.14
+2.09%
 
NTRA Natera, Inc.
91.66
+0.42%